Considering the role of p300 as a molecular target in hepatocellular carcinoma (HCC),[33, 34] we treated NR2E3‐depleted HepG2 cells (KO II) with a chemical inhibitor of p300, C646.[35] The treatment resulted in decreased expression of JAG1, PPARD, and β‐catenin, providing evidence for developing effective treatment via p300 inhibition to delay the progression of HCC expressing low NR2E3 and high β‐catenin (Figure 6M). This evidence concerns the gene PPARD and hepatocellular carcinoma.